Analysis of (Salvage-) Treatment of First Relapse in Patients with primary inoperable NSCLC in Stage III after initial Radio Chemotherapy

被引：0
|
作者：
Eze, C. [1 ]
Taugner, J. [1 ]
Roengvoraphoj, O. [1 ]
Schmidt-Hegemann, N. -S [1 ]
Dantes, M. [1 ]
Kaesmann, L. [1 ]
Belka, C. [1 ,2 ]
Manapov, F. [1 ,2 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Munich, Germany
[2] German Ctr Lung Res DZL, CPC M, Munich, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2019年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P19-11-jD
引用
收藏
页码：S141 / S142
页数：2
相关论文
共 50 条
  • [1] Induction chemotherapy in inoperable stage III α-β and IV NSCLC patients, evolution and survival
    Stathopoulos, GP
    Malamos, NA
    Papakostas, P
    Samelis, GF
    Rigatos, S
    Moschopoulos, N
    Papazachariou, A
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [2] Evaluation of outcome and toxicity of Durvalumab treatment after CRT in inoperable stage III NSCLC
    Kaesmann, L.
    Taugner, J.
    Eze, C.
    Roengvoraphoj, O.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S532 - S532
  • [3] NK cell expansion after primary multimodal treatment to predict progression free survival in inoperable stage III NSCLC
    Hofer, Thomas Philipp
    Kasmann, Lukas
    Nieto, Alexander
    Pelikan, Carolyn
    Taugner, Julian
    Eze, Chukwuka
    Tufman, Amanda
    Belka, Claus
    Manapov, Farkhad
    Noessner, Elfriede
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] SALVAGE TREATMENT OF PATIENTS SUFFERING RELAPSE AFTER ADJUVANT CMF CHEMOTHERAPY
    VALAGUSSA, P
    TANCINI, G
    BONADONNA, G
    CANCER, 1986, 58 (07) : 1411 - 1417
  • [5] Pathological response rates after induction radio-chemotherapy in stage III NSCLC
    Casas, F.
    Sanchez, D.
    Martinez, D.
    Boada, M.
    Vilarino, N.
    Martin, R.
    Paredes, P.
    Volmer, I.
    Cortes, K. S.
    Parera, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S68 - S68
  • [6] Analysis of the Influence of volumetric Radiation Parameters on the Overall Survival of Patients with inoperable Stage III NSCLC after Chemoradiotherapy
    Taugner, J.
    Kaesmann, L.
    Eze, C.
    Dantes, M.
    Roengvoraphoj, O.
    Belka, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S149 - S149
  • [7] Analysis of the Recurrence Pattern in Patients with unresectable Stage III NSCLC after primary Chemoradioimmunotherapy
    Taugner, J.
    Kasmann, L.
    Eze, C.
    Nieto, A.
    Bromberger, L.
    Guggenberger, J.
    Kenndoff, S.
    Florsch, B.
    Tufman, A.
    Reinmuth, N.
    Belka, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S107 - S107
  • [8] Durvalumab treatment after CRT in inoperable stage III NSCLC - a German radiation oncology survey
    Kaesmann, L.
    Taugner, J.
    Eze, C.
    Roengvoraphoj, O.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S532 - S533
  • [9] Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy
    Eze, C.
    Taugner, J.
    Kaesmann, L.
    Roengvoraphoj, O.
    Schmidt-Hegemann, N-S.
    Dantes, M.
    Belka, C.
    Manapov, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment
    Dickhoff, Chris
    Heineman, David Jonathan
    Bahce, Idris
    Senan, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : 1124 - 1128
12345